Your browser doesn't support javascript.
loading
Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.
Phillips, Elizabeth H; Devereux, Stephen; Radford, John; Mir, Naheed; Adedayo, Toyin; Clifton-Hadley, Laura; Johnson, Rod.
Afiliação
  • Phillips EH; Cancer Research UK and University College London Cancer Trials Centre , London , UK.
  • Devereux S; King's College Hospital NHS Foundation Trust , London , UK.
  • Radford J; University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre , Manchester , UK.
  • Mir N; Haematology Department, University Hospital Lewisham , London , UK.
  • Adedayo T; Cancer Research UK and University College London Cancer Trials Centre , London , UK.
  • Clifton-Hadley L; Cancer Research UK and University College London Cancer Trials Centre , London , UK.
  • Johnson R; Department of Haematology, Leeds Cancer Centre , Leeds , UK.
Leuk Lymphoma ; 60(9): 2291-2294, 2019 09.
Article em En | MEDLINE | ID: mdl-30773077
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Viroses / Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células T / Alemtuzumab / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials / Incidence_studies / Prognostic_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Viroses / Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células T / Alemtuzumab / Antineoplásicos Imunológicos Tipo de estudo: Clinical_trials / Incidence_studies / Prognostic_studies Limite: Adult / Aged / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article